Scientist received $150K to testify against Tylenol manufacturer for Trump

President Trump recently raised concerns about pregnant women giving birth to babies with autism due to the use of Tylenol, referencing a study conducted by Dr. Andrea Baccarelli. Dr. Baccarelli, a senior public health academic at Harvard University, co-authored a review linking acetaminophen, the active ingredient in Tylenol, to autism, advising pregnant women to limit their consumption of the drug. Despite the presence of this potentially alarming information, there have been revelations about Dr. Baccarelli’s involvement in a class action lawsuit against Kenvue, the maker of Tylenol, in 2023. During the lawsuit, Baccarelli served as an expert witness and received $150,000 for his testimony.

The credibility of Dr. Baccarelli’s research and testimony has come into question following the dismissal of testimonies from five experts, including Baccarelli, in the class action lawsuit. Federal judge, Denise Cote, found their views to be unreliable and aimed at obfuscating rather than enlightening. Specifically, Cote criticized Baccarelli’s discussion as incomplete, unbalanced, and misleading, emphasizing that his assertions overlooked contradictory evidence. It was also discovered that Baccarelli’s expert testimony during the lawsuit was later used in the study published last month, raising questions about the validity of his research.

Criticism of Baccarelli’s research extends beyond the courtroom, with members of the scientific community questioning the methodology and conclusions drawn by the Harvard academic. Professor David Mandell from the Centre for Autism Research at the Children’s Hospital of Philadelphia highlighted concerns regarding bias and the lack of rigorous evidence review in Baccarelli’s study. The scientific community has also expressed skepticism about the conclusions drawn by Baccarelli, indicating that studies on the link between Tylenol and autism are inconclusive and inconsistent.

While some studies suggest a potential link between prenatal exposure to Tylenol and autism, such findings have been contradicted by other research. For instance, a large-scale study funded by the US government found evidence that the association between acetaminophen use during pregnancy and autism disappeared when comparing siblings with varying exposure levels. The study emphasized that environmental and other factors may play a more significant role than the drug itself in determining outcomes.

In response to concerns raised by Dr. Baccarelli’s research and the subsequent public advisory against Tylenol consumption during pregnancy, the scientific community has urged caution. The Autistic Self Advocacy Network and the Coalition for Autism Scientists have questioned the reliability and consistency of studies linking Tylenol to autism, emphasizing the need for nuanced and thorough research. They highlight the potential dangers of making definitive claims without substantial evidence and assert that the existing data do not conclusively support the notion that Tylenol causes autism.